Kornimate/medical-research-clean huggingface dataset:
the clinical investigation of colgate dual zinc toothpaste as compared to colgate cavity protection toothpaste in controlling established plaque and gingivitis

Conditions: Plaque, Dental; Gingivitis

Summary: qualified subjects will be enrolled and randomized to either one of the two study groups described above based on their initial plaque and gingivitis scores. subjects will be instructed to use the products according to the instructions provided. subjects will return to the dental office for evaluation after three months of product use. all subjects will be followed for adverse events throughout the study.


Eligibility criteria:
inclusion criteria: * subjects, ages 18-70, inclusive. * availability for the three-month duration of the clinical research study. * good general health. * minimum of 20 uncrowned permanent natural teeth (excluding third molars). * initial gingivitis index of at least 1.0 as determined by the use of the loe and silness gingival index. * initial plaque index of at least 1.5 as determined by the use of the quigley and hein plaque index (turesky modification). * signed informed consent form exclusion criteria: * presence of orthodontic bands. * presence of partial removable dentures. * tumor(s) of the soft or hard tissues of the oral cavity. * advanced periodontal disease (purulent exudate, tooth mobility, and/or extensive loss of periodontal attachment or alveolar bone). * five or more carious lesions requiring immediate restorative treatment. * antibiotic use any time during the one month prior to entry into the study. * participation in any other clinical study or test panel within the one month prior to entry into the study. * dental prophylaxis during the past two weeks prior to baseline examinations. * history of allergies to oral care/personal care consumer products or their ingredients. * on any prescription medicines that might interfere with the study outcome. * an existing medical condition which prohibits eating or drinking for periods up to 4 hours. * history of alcohol or drug abuse. * pregnant or lactating subjects
inhibition transcranial random noise stimulation

Conditions: Impulsive Behavior; Inhibition

Summary: inhibition control deficits is a major risk factor in the transition to the act in suicidal patients. neuroimaging studies have shown that this failure was associated with hypoactivity in the prefrontal cortex (pfc), a brain area involved in the control of impulsivity. it was recently shown that a noninvasive brain stimulation session applied on the pfc reduces transiently impulsivity in healthy volunteers. noninvasive brain stimulation modulates the activity and connectivity of neural network connected to the stimulation site. the investigators assume that a repetition of noninvasive brain stimulation sessions on the pfc will allow a more intense and longer lasting effect on impulsivity and cognitive control in healthy volunteers compared to a single session and to placebo stimulation. the investigators assume that this behavioral change will be accompanied by a change in brain activity measured by resting eeg for the patients in the active group. a more intense and longer lasting effect is an essential step to transfer these results to patient populations. the main objective is to study the effect of bilateral stimulation of the pfc by transcranial random noise stimulation (trns) on the inhibition control measured by the cognitive motor inhibition capacity (go nogo test). the secondary objectives are to study the effect of trns on verbal inhibition (measured with the hayling test); on anxiety (measured with the state-trait anxiety inventory (stai)),on angry (measured with the state-trait anger expression inventory (staxi)) on verbal and nonverbal inhibition (measured by the stroop test), on impulsive behavior (measured by the barrat impulsiveness scale (bis 10)) and on the neuronal electrical activity measured by eeg.

subjects are stimulated 3 times in a day. each 20 minutes stimulation are separated by a period of at least 30 minutes. before and after each stimulation, inhibition is evaluated by cognitive tests (go nogo test, stroop test, hayling test) and by the bis 10 scale. during the stimulation, subjects compleat the staxi and stai scales. cognitive tests are repeated 24 hours and 8 days after the stimulation to evaluate duration of the effect. possible side effects will be notified throughout the protocol.

Eligibility criteria:
inclusion criteria: * age between 18 and 45 years exclusion criteria: * inability to give consent * under 18 years * over 45 years * pregnant women * nursing mothers * history of neurological or psychiatric disorders and personality disorders in cluster impulsivity (cluster b) according to diagnostic and statistical manual (dsm) iv * french national adult reading test (fnart): score below the 5th percentile * contraindications to the practice of transcranial brain stimulation as international safety recommendations (rossi et al., 2009) * processing or recent psychotropic
economic burden in adult patients diagnosed with rheumatoid arthritis (ra) receiving treatment with biologic disease-modifying antirheumatic drugs (bdmards)

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to explore the differences in productivity loss and costs between patients being treated for rheumatoid arthritis (ra) with biologic disease-modifying antirheumatic drugs (bdmards) compared to patients treated with conventional dmards.

time perspective: prospective with some retrospective analysis of claims data

Eligibility criteria:
inclusion criteria: * evidence of a bdmard or dmard during the identification period (01 february 2009 - 31 july 2009) * 18 years of age or older at the index year * at least 12 months of continuous enrollment in a large commercial us health plan affiliated with i3 innovus, including the at least 6 months and up to 12 months prior the index date (i.e., the pre-index period) and at least 6 months following the index date (i.e., the post-index (follow-up) period) * diagnosis of ra (reported on baseline survey) exclusion criteria: * diagnosis of psoriasis, plaque psoriasis, or psoriatic arthritis (icd-9 code 696.0x, or 696.1x), ankylosing spondylitis (720.0x), crohn's disease (555.x), non-hodgkins lymphoma (200.xx, 202.0x-202.2x, 202.7x-202.8x), or ulcerative colitis (556.x) in any position at any time during the 18-month identification period
personality characteristics and compliance with antiglaucoma medication

Conditions: Glaucoma

Summary: personality traits may influence to the drug compliance in glaucoma patients.

in chronic diseases, especially asymptomatic at early stage, drug compliance has been reported as an important factor to control them. and personality traits are associated with the drug compliance. however, there was few study to consider this relationship. we want to find the association the personality characteristics and drug compliance in glaucoma patients.

Eligibility criteria:
inclusion criteria: * chronic glaucoma * topical anti-glaucoma medications exclusion criteria: * oral glaucoma medications

Keywords: glaucoma drug compliance personality
the efficacy of quadruple therapy containing sodium bicarbonate as the primary treatment for helicobacter pylori infection

Conditions: Helicobacter Pylori Infection

Summary: the goal of this clinical trial is to learn the efficacy of sodium bicarbonate-containing quadruple therapy as the primary treatment for helicobacter pylori infection. the main questions it aims to answer are: can sodium bicarbonate replace bismuth or clarithromycin in the classic quadruple therapy for the primary treatment of helicobacter pylori infection? what is the safety and cost-effectiveness of sodium bicarbonate replacing bismuth or clarithromycin in the classic quadruple therapy for the primary treatment of helicobacter pylori infection? researchers will compare sodium bicarbonate replacing bismuth or clarithromycin in the classic quadruple therapy to see the efficacy of sodium bicarbonate as an alternative to bismuth or clarithromycin in the classic quadruple therapy for the primary treatment of helicobacter pylori infection. participants will： take helicobacter pylori treatment drugs for 14 days recheck 13c-ubt or 14c-ubt breath test 6-8 weeks after eradication treatment incidence of adverse reactions (aes) and patient compliance


Eligibility criteria:
inclusion criteria: * aged 18-65 years, no history of eradication therapy; * diagnosed with helicobacter pylori infection by one or more of the following methods: gastric mucosal histochemical staining, tissue culture, 14c-ubt, 13c-ubt and/or fecal antigen; * patients with warning symptoms, family history of gastric cancer or over 40 years old should undergo endoscopic examination before eradication therapy; * voluntarily participate in clinical trials and sign informed consent. exclusion criteria: * use of antibiotics or bismuth within 4 weeks before enrollment, or use of acid suppressants (including h2ra, ppi or p-cab) within 2 weeks; * active peptic ulcer with complications such as bleeding, perforation or obstruction; * history of esophagectomy or gastrectomy; * allergy to any study drug; * pregnancy or lactation; * history of alcoholism or drug abuse; * mental illness; * incapacity for civil conduct.

Keywords: helicobacter pylori sodium bicarbonate
fetal front-abdominal wall thickness and perinatal outcome

Conditions: Fetal Macrosomia; Abdominal Wall Mass; Perinatal Problems

Summary: abnormal fetal development such as macrosomia can cause some complications on both fetus and mother.the measurement of fetal anterior abdominal wall thickness (fawt) is an easy examination that it can be obtained during an examination of a pregnant woman by ultrasound. macrosomia for fetus can lead to some morbidities. it can affect perinatal outcome and increase childbirth complications and operative birth. there are some studies scrutinizing the relationship between fawt and diabetes in the literature. however there are few studies which scrutinize effect of fawt on both abnormal fetal development and adverse perinatal outcomes in non-diabetic pregnancies and non high risk pregnancies. hence the investigators wonder if fawt can anticipate birth-weight or macrosomic infant or perinatal outcome regarding with macrosomia in the second trimester.


Eligibility criteria:
inclusion criteria: a total of 96 women with low risk pregnancy coming to our clinic for a routine antenatal examination in 26-28th gestational weeks were included to this study and performed 75 gr- oral glucose tolerance test (ogtt). exclusion criteria: the participants with a positive 75-g ogtt were excluded. additionally those following criteria were accepted as the exclusion criteria of this study: hypertension, preeclampsia, diabetes, fetal distress, fetal anomaly, multiple pregnancy, preterm labor, preterm premature rupture of membrane, placenta previa, polyhydramnios and intrauterine fetal growth restriction.

Keywords: fetal macrosomia fetal abdominal wall thickness subcutaneous adipose tissue
effect of bevacizumab and vegf on platelet clustering in patients who are receiving bevacizumab for cancer

Conditions: Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific

Summary: rationale: studying samples of blood from patients with cancer in the laboratory may help doctors learn more about the effect of bevacizumab and vegf on platelet clustering. purpose: this research study is looking at the effect of bevacizumab and vegf on platelet clustering in patients with cancer who are receiving bevacizumab.

objectives: * to determine the influence of bevacizumab on platelet aggregation in patients receiving bevacizumab for cancer. * to determine the influence of vegf on platelet aggregation. * to determine the influence of vegf or bevacizumab on cyclooxygenesis. * to determine if the sequence of medication plays a role in platelet aggregation. outline: blood samples are collected before and after bevacizumab infusion. samples are analyzed for measurements of platelet aggregation, coagulation parameters, and endothelial activation (e.g., fibrin fragment f1 and 2, thrombin and antithrombin complex, soluble p-selectin, von willebrand factor and factor viii, tissue factor, and endothelin 1).

Eligibility criteria:
disease characteristics: * receiving bevacizumab for cancer patient characteristics: * not specified prior concurrent therapy: * see disease characteristics

Keywords: unspecified adult solid tumor, protocol specific unspecified childhood solid tumor, protocol specific
times: ticagrelor vs. placebo/ clopidogrel with aspirin in anterior stemi patients treated with primary pci

Conditions: ST Elevation Myocardial Infarction

Summary: this is a single-centred, double blind randomized controlled trial comparing ticagrelor with placebo in clopidogrel and aspirin loaded patients.

the very early benefit of ticagrelor in stemi is co-mediated by adenosine cardioprotection maintaining/ improving myocardial microcirculatory function, as well as via platelet inhibition or possibly other pleiotropic effects. ticagrelor increases circulating adenosine by reducing cellular re-uptake. adenosine is a cardioprotective agent that utilizes cellular survival kinase pathways that may have beneficial effects on the microcirculation and myocardium in patients presenting with stemi. adenosine is currently used as a treatment for no-reflow and improves mvo post-stemi when administered during ppci. a recent study of healthy volunteers has confirmed that non-invasive coronary flow is augmented by ticagrelor and that this is mediated by adenosine. the investigators propose that the very early beneficial effects of ticagrelor in acs may be adenosine mediated cardioprotection, rather than only due to an antiplatelet effect. this important research is original and a natural progression of the ticagrelor story. it expands the adenosine hypothesis and mode of action of ticagrelor and addresses a novel cardioprotective/ microcirculatory mechanism of action.

Eligibility criteria:
inclusion criteria: 1. provision of informed verbal consent prior to any study specific procedures taking place with written consent confirmed prior to in-patient cardiac mri. 2. male or female adult patient aged 18 - 90 years old 3. anterior stemi (st elevation ≥ 2mmhg in contiguous chest leads) with chest pain symptom onset \< 12 hours exclusion criteria: 1. cardiogenic shock\* 2. previous anterior myocardial infarction 3. unfavourable coronary anatomy for pci: left main / surgical or distal coronary disease 4. already prescribed ticagrelor at the time of admission 5. factors affecting study drug administration/ absorption: vomiting or allergy 6. concomitant use of potent cyp3a4 inhibitors/ inducers (e.g ketoconazole and rifampicin) or cyp3a4 substrates with a narrow therapeutic window (e.g. cisapride and ergot alkaloids) or simvastatin / lovostatin \>40mg oral dose. 7. severe bleeding diathesis or current active bleeding\* 8. history of intracranial haemorrhage 9. moderate or severe hepatic impairment 10. severe asthma or bradycardia/ complete heart block (contraindications to adenosine)\* 11. severe co-morbidity with a life expectancy \< 3 months. 12. women of child bearing potential (as determined by direct questioning of the patient to confirm and this will be documented in the medical notes). * patients that are found to have any excluding factor (e.g., unfavourable coronary anatomy for pci) or develop any excluding factor (e.g., vomiting or cardiogenic shock) before the point of final imr assessment will be discontinued from the study and followed up at discharge and by telephone at 3 and 12 months for adverse event monitoring purposes only.
phase ib study of pdr001 in combination with regorafenib in adult patients with previously treated metastatic colorectal cancer

Conditions: Metastatic Colorectal Cancer

Summary: this was a phase ib study of pdr001 in combination with regorafenib in adult patients with previously treated metastatic microsatellite stable (mss) colorectal cancer. the study assessed primarily the safety and tolerability of pdr001 in combination with regorafenib.


Eligibility criteria:
key inclusion criteria: 1. patients with metastatic colorectal adenocarcinoma. 2. patients must provide a newly obtained or an archival tumor sample corresponding to crc diagnosis (primary tumor) with sufficient tissue quality (qualified) for analysis 3. patients must provide a newly obtained tumor tissue sample from a metastatic site 4. patients with the presence of at least one lesion with measurable disease as per recist 5. patients previously treated with two prior regimen as per standard of care and have experienced disease progression (including -vegf and egfr targeted therapies (if kras wild). 6. patient has an eastern cooperative oncology group (ecog) performance status 0-1 key exclusion criteria: 1. patients with msi-h colorectal adenocarcinoma as defined per local assessment using standard of care testing 2. patients with metastatic disease amenable to be resected with potentially curative surgery 3. patients who have had chemotherapy, radiation, or biological cancer therapy within 14 days prior to the first dose of study treatment 4. patients with a history of prior treatment with anti-pd-1, anti-pd-l1, anti-pdl2, anti- ctla-4 antibodies, other checkpoint inhibitors

Keywords: pdr001 mcc immunotherapy regorafenib crc mms cms4 elevation:crc-102
chinese medicinal herbs treatment on novel influenza a (h1n1) : multi-centre, prospective, randomized controlled study

Conditions: Influenza

Summary: the purpose of this study is to determine whether chinese medicinal herbs are effective and safe for treating novel influenza a (h1n1) infection.

the antiviral agent, oseltamivir, is recommended by the world health organization (who) to treat recent outbreak novel influenza a (h1n1) virus infection around world. but limited stock and resistant strain emergence raised increasing concerns. chinese medicinal herbs, are derived from plants and usually incorporate one or more herbs as the basic drug(s) to treat the disease. the investigators performed rct to indicate that chinese medicinal herbs was effective and safe for treating novel influenza a (h1n1) infection.

Eligibility criteria:
inclusion criteria: * confirmed novel influenza a(h1n1) case with laboratory evidence * 70 years ≥ age ≥ 14years * within 72hr after the onset of symptoms(body temperature≥37.5℃ with at least one respiratory symptom (cough, sore throat, or nasal symptom) exclusion criteria: * age \ 70 years * bronchitis, pneumonia, pleural fluid and interstitial infiltration showed by chest radiology(x-ray or ct) * severe chronic underlying diseases: severe copd(fev1/evc \ 2mg/dl), chronic heart failure(nyha ⅲ-ⅳ grade） * immunocompromised patients(cancer, organ transplant, aids and a history of treatment with immunosuppressive drug and glucocorticoids in the past 3 months) * taken chinese medicinal herbs, antiviral or antibiotic drug in the past 2 weeks * inoculation influenza vaccination * one of the following items appeared at the enrollment * respiratory failure：pao2\ 50mmhg or pao2/fio2≤300 * circulation failure: despite adequate fluid resuscitation and cardiac output, systolic \<90mmhg or requirement inotropic support * renal function failure: despite adequate fluid resuscitation and cardiac output, urine ≤ 0.5ml/kg.h, cr or bun≥1 time normal elevation * hepatic function failure: total bilirubin\>34μmol/l or alt/ast ≥3 times normal - other unappropriated enrollment situations considered by investigator

Keywords: novel influenza a(h1n1) oseltamivir chinese medicinal herbs
hemodilution and outcome in cardiac surgery

Conditions: Kidney Failure; Intraoperative Complications

Summary: an hematocrit of 21-25% is supposed to perform the best organ protection during cardiopulmonary bypass for cardiac surgery. the investigators want to establish the best timing for a transfusion (in patients with a predicted low hematocrit during cardiopulmonary bypass) and the efficacy of preprocedural hemodilution (in patients with a predicted high hematocrit during cardiopulmonary bypass) in patients undergoing cardiac surgery.


Eligibility criteria:
inclusion criteria: * undergoing cardiac surgery exclusion criteria: * age \< 18 years old * not signing written consent * age \< 65 years old (subgroup 1) * emergency, aortic stenosis, main left coronary stenosis (subgroup 2)

Keywords: hematocrit hemodilution blood transfusion cardiopulmonary bypass multiple organ failure surgery, cardiac kidney failure cardiac surgical procedures
functional scaffold transplantation combined with epidural electrical stimulation for spinal cord injury repair

Conditions: Spinal Cord Injury

Summary: the study is designed to assess the role of functional neural regeneration collagen scaffold transplantation combined with epidural electrical stimulation in spinal cord injury patients.


Eligibility criteria:
inclusion criteria: the enrolled participants are divided into three categories: 1. participants had complete functional scaffold transplantation in previous study and had motor functional recovery 2. participants with acute complete sci: (1) classification asia a, occurring within past 14 days; (2) completely spinal cord injury at neurological level c4- t12/l1; (3) no serious complications 3. participants with chronic complete sci: (1) classification asia a, greater than 6 months post injury and no significant further improvement within past 3 months; (2) completely spinal cord injury at neurological level c4- t12/l1; (3) peripheral nervous system in good condition; (4) no serious complications inclusion criteria for all the participants 1. men or non-pregnant women, 18-60 years old 2. ability and willingness to regular visit to hospital and follow up during the protocol procedures 3. accompanied by a family member 4. signed informed consent exclusion criteria: 1. obvious muscle atrophy or fibrosis 2. decline in peripheral nerve function 3. a current diagnosis of diseases affecting spinal cord injury recovery or rehabilitation training (e.g., brain injury, cerebral hemorrhage, cognitive impairment, other central nervous system diseases) 4. having serious health problems, (e.g., cardiovascular disease, diabetes, autoimmune diseases, tumors or severe hypertension) or serious complications (e.g. severe bedsores, pulmonary infection, respiratory disorders) 5. pregnancy or lactation 6. history of mental illness or suicide risk, with a history of epilepsy or other central nervous system disorders 7. no family member accompany or can not get in touch with family members 8. poor compliance, difficult to complete the study 9. any other conditions that might increase the risk of participants or interfere with the clinical trial